Attenuation of colitis by Lactobacillus casei BL23 is dependent on the dairy delivery matrix

Applied and Environmental Microbiology

Volumn 81, Issue 18, 2015, Pages 6425-6435

  Lee, Bokyung ^a   Yin, Xiaochen ^a   Griffey, Stephen M ^a   Marco, Maria L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DISEASES; FOOD MICROBIOLOGY; NUTRIENTS; RNA; SODIUM SULFATE;

16S RRNA GENE SEQUENCING; DEXTRAN SULFATE SODIUM; INTESTINAL INFLAMMATION; LACTOBACILLUS CASEI; LIPOTEICHOIC ACIDS; NUTRITIONAL SUPPLEMENTS; PRO-INFLAMMATORY CYTOKINES; ULCERATIVE COLITIS;

DAIRIES;

BACTERIUM; GENE EXPRESSION; IMMUNE RESPONSE; MILK; MUTAGENICITY; PROBIOTICS; RODENT;

ANIMALIA; BIFIDOBACTERIACEAE; COMAMONADACEAE; LACTOBACILLUS CASEI; MURINAE; MUS;

BACTERIAL PROTEIN; CYTOKINE; DEXTRAN SULFATE; DLTD PROTEIN, BACTERIA; PROBIOTIC AGENT; RECA PROTEIN; RNA 16S; THIOL ESTER HYDROLASE;

ANIMAL; BIOSYNTHESIS; COLITIS; COMAMONADACEAE; DISEASE MODEL; FECES; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INTESTINE; INTESTINE FLORA; ISOLATION AND PURIFICATION; LACTOBACILLUS CASEI; MICROBIAL VIABILITY; MICROBIOLOGY; MILK; MOUSE; PHYSIOLOGY;

ANIMALS; BACTERIAL PROTEINS; COLITIS; COMAMONADACEAE; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FECES; GASTROINTESTINAL MICROBIOME; INTESTINES; LACTOBACILLUS CASEI; MICE; MICROBIAL VIABILITY; MILK; PROBIOTICS; REC A RECOMBINASES; RNA, RIBOSOMAL, 16S; THIOLESTER HYDROLASES;

EID: 84945266126     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01360-15     Document Type: Article

References (77)

1. Sanders ME, Klaenhammer TR, Ouwehand AC, Pot B, Johansen E, Heimbach JT, Marco ML, Tennila J, Ross RP, Franz C, Page N, Pridmore RD, Leyer G, Salminen S, Charbonneau D, Call E, Lenoir-Wijnkoop I. 2014. Effects of genetic, processing, or product formulation changes on efficacy and safety of probiotics. Ann N Y Acad Sci 1309:1-18. http://dx.doi.org/10.1111/nyas.12363.
2. Sanders ME, Marco ML. 2010. Food formats for effective delivery of probiotics. Annu Rev Food Sci Technol 1:65-85. http://dx.doi.org/10 .1146/annurev.food.080708.100743.
3. Saxelin M, Tynkkynen S, Mattila-Sandholm T, de Vos WM. 2005. Probiotic and other functional microbes: from markets to mechanisms. Curr Opin Biotechnol 16:204-211. http://dx.doi.org/10.1016/j .copbio.2005.02.003.
4. Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EMM, Sartor RB, Sherman PM, Mayer EA. 2013. An update on the use and investigation of probiotics in health and disease. Gut 62:787-796. http://dx.doi.org /10.1136/gutjnl-2012-302504.
5. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. 2014. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506-514. http://dx .doi.org/10.1038/nrgastro.2014.66.
6. Floch MH. 2014. Recommendations for probiotic use in humans-a 2014 update. Pharmaceuticals (Basel) 7:999-1007. http://dx.doi.org/10.3390 /ph7100999.
7. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. 2014. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 7:473-487. http://dx.doi.org/10.2147/CEG.S27530.
8. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, Grisham MB. 2002. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 33:311-322. http://dx.doi.org /10.1016/S0891-5849(02)00853-5.
9. Rezaie A, Parker RD, Abdollahi M. 2007. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52:2015-2021. http://dx.doi.org/10.1007/s10620-006-9622-2.
10. Kaser A, Zeissig S, Blumberg RS. 2010. Inflammatory bowel disease. Annu Rev Immunol 28:573-621. http://dx.doi.org/10.1146/annurev-immunol-030409-101225.
11. Meijer BJ, Dieleman LA. 2011. Probiotics in the treatment of human inflammatory bowel diseases. Update 2011. J Clin Gastroenterol 45:S139-S144.
12. Veerappan GR, Betteridge J, Young PE. 2012. Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep 14:324-333. http://dx.doi.org/10.1007/s11894-012-0265-5.
13. Whelan K, Quigley EM. 2013. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 29:184-189. http://dx.doi.org/10.1097/MOG.0b013e32835d7bba.
14. Shen J, Zuo ZX, Mao AP. 2014. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 20:21-35. http://dx.doi.org/10.1097/01.MIB.0000437495.30052.be.
15. Pedone CA, Bernabeu AO, Postaire ER, Bouley CF, Reinert P. 1999. The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114 001) on acute diarrhoea in children attending day care centres. Int J Clin Pract 53:179-184.
16. Pedone CA, Arnaud CC, Postaire ER, Bouley CF, Reinert P. 2000. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract 54:568-571.
17. Mazlyn MM, Nagarajah LHL, Fatimah A, Norimah AK, Goh KL. 2013. Effects of a probiotic fermented milk on functional constipation: a randomized, double-blind, placebo-controlled study. J Gastroenterol Hepatol 28:1584-1584. http://dx.doi.org/10.1111/jgh.12353.
18. Aoki T, Asahara T, Matsumoto K, Takada T, Chonan O, Nakamori K, Nonaka C, Yamaji I, Hisamoto T, Sato M, Matsuda T, Nomoto K. 2014. Effects of the continuous intake of a milk drink containing Lactobacillus casei strain Shirota on abdominal symptoms, fecal microbiota, and metabolites in gastrectomized subjects. Scand J Gastroenterol 49:552-563. http://dx.doi.org/10.3109/00365521.2013.848469.
19. Llopis M, Antolin M, Carol M, Borruel N, Casellas F, Martinez C, Espin-Basany E, Guarner F, Malagelada JR. 2009. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm Bowel Dis 15:275-283. http://dx.doi.org/10.1002/ibd.20736.
20. Peluso I, Fina D, Caruso R, Stolfi C, Caprioli F, Fantini MC, Caspani G, Grossi E, Di Iorio L, Paone FM, Pallone F, Monteleone G. 2007. Lactobacillus paracasei subsp. paracasei B21060 suppresses human T-cell proliferation. Infect Immun 75:1730-1737. http://dx.doi.org/10.1128/IAI .01172-06.
21. Ingrassia I, Leplingard A, Darfeuille-Michaud A. 2005. Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells. Appl Environ Microbiol 71:2880-2887. http://dx.doi.org /10.1128/AEM.71.6.2880-2887.2005.
22. Peran L, Camuesco D, Comalada M, Bailon E, Henriksson A, Xaus J, Zarzuelo A, Galvez J. 2007. A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis. J Appl Microbiol 103:836-844. http://dx.doi.org/10.1111/j.1365-2672.2007.03302.x.
23. Chung YW, Choi JH, Oh TY, Eun CS, Han DS. 2008. Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice. Clin Exp Immunol 151:182-189.
24. Herias MV, Koninkx JFJG, Vos JG, Huis in't Veld JHJ, van Dijk JE. 2005. Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice. Int J Food Microbiol 103:143-155. http://dx.doi.org/10 .1016/j.ijfoodmicro.2004.11.032.
25. Kokesova A, Frolova L, Kverka M, Sokol D, Rossmann P, Bartova J, Tlaskalova-Hogenova H. 2006. Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiol (Praha) 51:478-484. http://dx.doi.org/10.1007/BF02931595.
26. Rochat T, Bermudez-Humaran L, Gratadoux JJ, Fourage C, Hoebler C, Corthier G, Langella P. 2007. Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSSinduced colitis in mice. Microb Cell Fact 6:22. http://dx.doi.org/10.1186 /1475-2859-6-22.
27. von Schillde MA, Hormannsperger G, Weiher M, Alpert CA, Hahne H, Bauerl C, van Huynegem K, Steidler L, Hrncir T, Perez-Martinez G, Kuster B, Haller D. 2012. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host Microbe 11:387-396. http://dx.doi.org/10.1016/j .chom.2012.02.006.
28. Watterlot L, Rochat T, Sokol H, Cherbuy C, Bouloufa I, Lefevre F, Gratadoux JJ, Honvo-Hueto E, Chilmonczyk S, Blugeon S, Corthier G, Langella P, Bermudez-Humaran LG. 2010. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol 144:35-41. http://dx.doi.org/10.1016/j.ijfoodmicro.2010.03.037.
29. Douillard FP, Kant R, Ritari J, Paulin L, Palva A, de Vos WM. 2013. Comparative genome analysis of Lactobacillus casei strains isolated from Actimel and Yakult products reveals marked similarities and points to a common origin. Microb Biotechnol 6:576-587. http://dx.doi.org/10.1111 /1751-7915.12062.
30. Claes IJ, Lebeer S, Shen C, Verhoeven TL, Dilissen E, De Hertogh G, Bullens DM, Ceuppens JL, Van Assche G, Vermeire S, Rutgeerts P, Vanderleyden J, De Keersmaecker SC. 2010. Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GGin experimental colitis. Clin Exp Immunol 162:306-314. http://dx.doi .org/10.1111/j.1365-2249.2010.04228.x.
31. Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, Dewulf J, Pot B, Hartung T, Hols P, Mercenier A. 2005. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci U S A 102:10321-10326. http://dx.doi .org/10.1073/pnas.0504084102.
32. Lebeer S, Claes IJJ, Vanderleyden J. 2012. Anti-inflammatory potential of probiotics: lipoteichoic acid makes a difference. Trends Microbiol 20: 5-10. http://dx.doi.org/10.1016/j.tim.2011.09.004.
33. van de Guchte M, Serror P, Chervaux C, Smokvina T, Ehrlich SD, Maguin E. 2002. Stress responses in lactic acid bacteria. Antonie Van Leeuwenhoek 82:187-216. http://dx.doi.org/10.1023/A:1020631532202.
34. Duwat P, Ehrlich SD, Gruss A. 1995. The recA gene of Lactococcus lactis: characterization and involvement in oxidative and thermal stress. Mol Microbiol 17:1121-1131. http://dx.doi.org/10.1111/j.1365-2958.1995.mmi_17061121.x.
35. Erill I, Campoy S, Barbe J. 2007. Aeons of distress: an evolutionary perspective on the bacterial SOS response. FEMS Microbiol Rev 31:637-656. http://dx.doi.org/10.1111/j.1574-6976.2007.00082.x.
36. Sambrook J, Maniatis T, Fritsch EF. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
37. Leloup L, Ehrlich SD, Zagorec M, Morel-Deville F. 1997. Singlecrossover integration in the Lactobacillus sake chromosome and insertional inactivation of the ptsI and lacL genes. Appl Environ Microbiol 63:2117-2123.
38. Mizoguchi A. 2012. Animal models of inflammatory bowel disease. Prog Mol Biol Transl Sci 105:263-320. http://dx.doi.org/10.1016/B978-0-12-394596-9.00009-3.
39. Tachon S, Lee B, Marco ML. 2014. Diet alters probiotic Lactobacillus persistence and function in the intestine. Environ Microbiol 16:2915-2926. http://dx.doi.org/10.1111/1462-2920.12297.
40. + T cells. J Immunol 158:2099-2106.
41. Yin X, Yan Y, Kim EB, Lee B, Marco ML. 2014. Short communication: effect of milk and milk containing Lactobacillus casei on the intestinal microbiota of mice. J Dairy Sci 97:2049-2055. http://dx.doi.org/10.3168 /jds.2013-7477.
42. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, Fierer N, Knight R. 2011. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A 108:4516-4522. http://dx.doi.org/10.1073/pnas.1000080107.
43. Bokulich NA, Joseph CML, Allen G, Benson AK, Mills DA. 2012. Next-generation sequencing reveals significant bacterial diversity of botrytized wine. PLoS One 7:e36357. http://dx.doi.org/10.1371/journal.pone.0036357.
44. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335-336. http://dx.doi.org/10.1038/nmeth.f.303.
45. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P, Andersen GL. 2006. Greengenes, a chimerachecked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 72:5069-5072. http://dx.doi.org/10.1128/AEM.03006-05.
46. Lozupone C, Knight R. 2005. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol 71:8228-8235. http://dx.doi.org/10.1128/AEM.71.12.8228-8235.2005.
47. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. 2011. Metagenomic biomarker discovery and explanation. Genome Biol 12:R60. http://dx.doi.org/10.1186/gb-2011-12-6-r60.
48. Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. 2014. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 104:Unit 15.25. http://dx.doi.org/10.1002/0471142735.im1525s104.
49. Baumgart DC, Sandborn WJ. 2007. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369:1641-1657. http://dx.doi.org/10.1016/S0140-6736(07)60751-X.
50. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola M, Li XH. 2009. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 15:341-352. http://dx.doi.org/10.1002/ibd.20753.
51. Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, Dewulf J, Brassart D, Mercenier A, Pot B. 2007. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 13:236-243. http://dx.doi.org/10.3748/wjg.v13.i2.236.
52. Mohamadzadeh M, Pfeiler EA, Brown JB, Zadeh M, Gramarossa M, Managlia E, Bere P, Sarraj B, Khan MW, Pakanati KC, Ansari MJ, O'Flaherty S, Barrett T, Klaenhammer TR. 2011. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A 108(Suppl 1):4623-4630. http://dx.doi.org /10.1073/pnas.1005066107.
53. Russ A, Barnett M, McNabb W, Anderson R, Reynolds G, Roy N. 2010. Post-weaning effects of milk and milk components on the intestinal mucosa in inflammation. Mutat Res 690:64-70. http://dx.doi.org/10.1016/j .mrfmmm.2009.12.006.
54. Cohen AB, Lee D, Long MD, Kappelman MD, Martin CF, Sandler RS, Lewis JD. 2013. Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci 58:1322-1328. http://dx.doi.org/10.1007/s10620-012-2373-3.
55. Hosoya T, Ogawa A, Sakai F, Kadooka Y. 2012. A cheese-containing diet modulates immune responses and alleviates dextran sodium sulfateinduced colitis in mice. J Dairy Sci 95:2810-2818. http://dx.doi.org/10 .3168/jds.2011-4763.
56. Sprong RC, Schonewille AJ, van der Meer R. 2010. Dietary cheese whey protein protects rats against mild dextran sulfate sodium-induced colitis: role of mucin and microbiota. J Dairy Sci 93:1364-1371. http://dx.doi.org /10.3168/jds.2009-2397.
57. Debabov DV, Kiriukhin MY, Neuhaus FC. 2000. Biosynthesis of lipoteichoic acid in Lactobacillus rhamnosus: role of DltD in D-alanylation. J Bacteriol 182:2855-2864. http://dx.doi.org/10.1128/JB.182.10.2855-2864.2000.
58. Palumbo E, Deghorain M, Cocconcelli PS, Kleerebezem M, Geyer A, Hartung T, Morath S, Hols P. 2006. D-Alanyl ester depletion of teichoic acids in Lactobacillus plantarum results in a major modification of lipoteichoic acid composition and cell wall perforations at the septum mediated by the Acm2 autolysin. J Bacteriol 188:3709-3715. http://dx.doi.org /10.1128/JB.188.10.3709-3715.2006.
59. Perea Velez M, Verhoeven TL, Draing C, Von Aulock S, Pfitzenmaier M, Geyer A, Lambrichts I, Grangette C, Pot B, Vanderleyden J, De Keersmaecker SC. 2007. Functional analysis of D-alanylation of lipoteichoic acid in the probiotic strain Lactobacillus rhamnosus GG. Appl Environ Microbiol 73:3595-3604. http://dx.doi.org/10.1128 /AEM.02083-06.
60. Tun X, Yasukawa K, Yamada K. 2014. Involvement of nitric oxide with activation of Toll-like receptor 4 signaling in mice with dextran sodium sulfate-induced colitis. Free Radic Biol Med 74:108-117. http://dx.doi.org /10.1016/j.freeradbiomed.2014.06.020.
61. Chiba Y, Shida K, Nagata S, Wada M, Bian L, Wang C, Shimizu T, Yamashiro Y, Kiyoshima-Shibata J, Nanno M, Nomoto K. 2010. Wellcontrolled proinflammatory cytokine responses of Peyer's patch cells to probiotic Lactobacillus casei. Immunology 130:352-362. http://dx.doi.org /10.1111/j.1365-2567.2009.03204.x.
62. Noto Llana M, Sarnacki SH, Aya Castaneda MR, Bernal MI, Giacomodonato MN, Cerquetti MC. 2013. Consumption of Lactobacillus casei fermented milk prevents Salmonella reactive arthritis by modulating IL-23/IL-17 expression. PLoS One 8:e82588. http://dx.doi.org/10.1371 /journal.pone.0082588.
63. Schiffer C, Lalanne AI, Cassard L, Mancardi DA, Malbec O, Bruhns P, Dif F, Daeron M. 2011. A strain of Lactobacillus casei inhibits the effector phase of immune inflammation. J Immunol 187:2646-2655. http://dx.doi .org/10.4049/jimmunol.1002415.
64. Kostic AD, Xavier RJ, Gevers D. 2014. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 146: 1489-1499. http://dx.doi.org/10.1053/j.gastro.2014.02.009.
65. Manichanh C, Borruel N, Casellas F, Guarner F. 2012. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9:599-608. http://dx.doi.org /10.1038/nrgastro.2012.152.
66. Rigottier-Gois L. 2013. Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. ISME J 7:1256-1261. http://dx.doi.org/10.1038/ismej .2013.80.
67. Fava F, Danese S. 2011. Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol 17:557-566. http://dx.doi.org /10.3748/wjg.v17.i5.557.
68. Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, Gonzalez A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ. 2014. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15:382-392. http: //dx.doi.org/10.1016/j.chom.2014.02.005.
69. Berry D, Schwab C, Milinovich G, Reichert J, Mahfoudh KB, Decker T, Engel M, Hai B, Hainzl E, Heider S. 2012. Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J 6:2091-2106. http://dx.doi.org/10.1038/ismej.2012.39.
70. De Fazio L, Cavazza E, Spisni E, Strillacci A, Centanni M, Candela M, Pratico C, Campieri M, Ricci C, Valerii MC. 2014. Longitudinal analysis of inflammation and microbiota dynamics in a model of mild chronic dextran sulfate sodium-induced colitis in mice. World J Gastroenterol 20:2051-2061. http://dx.doi.org/10.3748/wjg.v20.i8.2051.
71. Nagalingam NA, Kao JY, Young VB. 2011. Microbial ecology of the murine gut associated with the development of dextran sodium sulfateinduced colitis. Inflamm Bowel Dis 17:917-926. http://dx.doi.org/10.1002 /ibd.21462.
72. Bron PA, van Baarlen P, Kleerebezem M. 2011. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 10:66-78. http://dx.doi.org/10.1038/nrmicro2690.
73. Hemarajata P, Versalovic J. 2013. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol 6:39-51. http://dx.doi.org/10.1177 /1756283X12459294.
74. Sengupta R, Altermann E, Anderson RC, McNabb WC, Moughan PJ, Roy NC. 2013. The role of cell surface architecture of lactobacilli in hostmicrobe interactions in the gastrointestinal tract. Mediators Inflamm 2013:237921. http://dx.doi.org/10.1155/2013/237921.
75. Sanchez B, Urdaci MC, Margolles A. 2010. Extracellular proteins secreted by probiotic bacteria as mediators of effects that promote mucosabacteria interactions. Microbiology 156:3232-3242. http://dx.doi.org/10 .1099/mic.0.044057-0.
76. Marco ML, Tachon S. 2013. Environmental factors influencing the efficacy of probiotic bacteria. Curr Opin Biotechnol 24:207-213. http://dx .doi.org/10.1016/j.copbio.2012.10.002.
77. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. 2010. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 8:171-184. http://dx.doi.org/10.1038 /nrmicro2297.